Compass Pathways宣布,其核心候选药物Comp360在临床试验C部分的安防特性与此前的试验阶段呈现一致性,未观察到新的安全性问题。这一发现为药物的后续研发推进提供了积极信号。
Compass Pathways宣布,其核心候选药物Comp360在临床试验C部分的安防特性与此前的试验阶段呈现一致性,未观察到新的安全性问题。这一发现为药物的后续研发推进提供了积极信号。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.